Divalproex Sodium
Product Images NDC 33261-641

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 33261-641). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex-na-structure (Divalproex Sod Dr 250mg Tab For Sun 1)

Chemical structure of divalproex sodium showing the polymeric form with sodium carboxylate groups and branched alkyl chains.*

FDA Label Image

Divalproex-na-fig1 (Divalproex Sod Dr 250mg Tab For Sun 2)

Bar chart comparing the percentage efficacy of Divalproex sodium delayed-release tablets (DVPX) versus placebo (PBO) in two studies. Study 1 (YMRS) shows 26% for placebo and 60% for DVPX. Study 2 (MRS) shows 29% for placebo and 58% for DVPX. Asterisks indicate statistical significance (p < 0.05).*

FDA Label Image

Divalproex-na-fig2 (Divalproex Sod Dr 250mg Tab For Sun 3)

A bar chart comparing the effects of placebo and Divalproex Sodium delayed-release tablets across two studies. The y-axis appears to show a measured variable ranging from 0 to 6. Study 1 compares placebo to Divalproex Sodium at a mean dose of 1087 mg/day, while Study 2 compares placebo to Divalproex Sodium at doses of 500 or 1000 mg/day. The chart illustrates lower values for Divalproex Sodium groups compared to placebo in both studies.*

FDA Label Image

Divalproex-na-fig3 (Divalproex Sod Dr 250mg Tab For Sun 4)

A cumulative percentage plot showing the percent reduction in complex partial seizure (CPS) rate versus the percentage of patients. The graph compares Divalproex Sodium delayed-release tablets (DVPX) and placebo, illustrating patient improvements and worsening in seizure frequency.*

FDA Label Image

Divalproex-na-fig4 (Divalproex Sod Dr 250mg Tab For Sun 5)

A cumulative distribution plot showing the percentage reduction in CPS rate among patients treated with Divalproex Sodium at high and low doses. The x-axis represents the percentage of patients, and the y-axis represents the percentage reduction in CPS rate, ranging from -100% to 100%. Annotations indicate directions for worsening, no change, and improvement.*

FDA Label Image

Image Label (Divalproex Sod Dr 250mg Tab For Sun 6)

Label for Divalproex Sodium delayed-release tablets 250 mg, packaged by Aidarex Pharmaceuticals LLC. The label indicates 30 tablets per bottle, with each tablet containing valproic acid 250 mg. The tablets are orange oval with 'W797' imprinted on one side. The label references the generic equivalent Depakote and the manufacturer Sun Pharmaceutical Industries Ltd., Mumbai, India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.